AstraZeneca Plc AZN on Wednesday reported first-quarter 2026 results that topped Wall Street estimates, driven by strong ...

AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug candidates with potential advantages over ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

Learn more AstraZeneca posted first-quarter revenue of $15.29 billion and core earnings of $2.58 per share, topping analyst ...

AstraZeneca’s AZN third-quarter 2025 core earnings of $1.19 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.14 per share. Core earnings of $2.38 per share rose 14% year ...

The pharmaceutical company plans to invest $405.5 million in the U.K., reversing its previous decision to pause planned investments amid worries the country wasn’t rewarding innovation.

AstraZeneca PLC on Wednesday reported better-than-expected first-quarter revenue and profit, and flagged the potential for its drugs pipeline amid numerous positive trial findings and regulatory ...

SAN FRANCISCO--(BUSINESS WIRE)--Algen Biotechnologies, a biotechnology company pioneering next-generation therapies using advanced CRISPR gene modulation and AI-driven drug discovery, today announced ...

AstraZeneca ( (GB:AZN)) has shared an update. AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines across ...

AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...